INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 211 filers reported holding INTRA CELLULAR THERAPIES INC in Q4 2021. The put-call ratio across all filers is 0.45 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $70,061 | -10.2% | 1,345 | +9.2% | 0.00% | -33.3% |
| Q2 2023 | $78,010 | +16.9% | 1,232 | 0.0% | 0.00% | +50.0% |
| Q1 2023 | $66,713 | -49.7% | 1,232 | -50.8% | 0.00% | -66.7% |
| Q4 2022 | $132,512 | +13.3% | 2,504 | -0.1% | 0.01% | +20.0% |
| Q3 2022 | $117,000 | -18.2% | 2,507 | +0.1% | 0.01% | -28.6% |
| Q2 2022 | $143,000 | -5.9% | 2,504 | -0.9% | 0.01% | +16.7% |
| Q1 2022 | $152,000 | +10.1% | 2,526 | -4.5% | 0.01% | +20.0% |
| Q4 2021 | $138,000 | +39.4% | 2,644 | -0.2% | 0.01% | +25.0% |
| Q3 2021 | $99,000 | -2.9% | 2,650 | +6.0% | 0.00% | 0.0% |
| Q2 2021 | $102,000 | +20.0% | 2,500 | 0.0% | 0.00% | 0.0% |
| Q1 2021 | $85,000 | +6.2% | 2,500 | 0.0% | 0.00% | 0.0% |
| Q4 2020 | $80,000 | +25.0% | 2,500 | 0.0% | 0.00% | 0.0% |
| Q3 2020 | $64,000 | – | 2,500 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ally Bridge Group (NY) LLC | 175,000 | $9,115,750 | 10.70% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 317,856 | $16,547,583 | 5.57% |
| Deep Track Capital, LP | 2,600,000 | $135,434,000 | 5.23% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,369,849 | $71,355,434 | 3.86% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 208,730 | $10,872,746 | 3.30% |
| DCF Advisers, LLC | 107,157 | $5,581,808 | 3.04% |
| Bellevue Group AG | 3,170,250 | $165,138,323 | 2.66% |
| Vahanian & Associates Financial Planning Inc. | 15,217 | $792,654 | 2.55% |
| Iron Triangle Partners LP | 330,549 | $17,218,297 | 2.52% |
| TANG CAPITAL MANAGEMENT LLC | 300,000 | $15,627,000 | 2.20% |